FibroBiologics (Direct Listing) FBLG 深 滬
等待開盤 11-26 09:30:00 美东时间
0.268
+0.008
+3.08%
華盛通- 最 高0.28
- 今 開0.2611
- 成交量 298.48万股
- 最 低 0.2501
- 昨 收 0.26
- 總市值 1379.02万
- 52周最高 2.55
- 市盈率 靜 --
- 換手率 5.80%
- 52周最低 0.24
- 委 比 -63.27%
- 總股本 5145.61万
- 歷史最高 55.00
- 量 比 1.60
- 振 幅 11.50%
- 歷史最低 0.24
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
D. Boral Capital Maintains Buy on FibroBiologics, Maintains $15 Price Target
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $15 price target.
11-20 21:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
11-20 05:07
FibroBiologics shares are trading lower after the company priced a $4 million registered direct offering.
FibroBiologics shares are trading lower after the company priced a $4 million r...
11-19 21:38
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $5
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price target from $10 to $5.
11-05 19:29
Watching FibroBiologics; Zacks Small-Cap Research Gives Stock $11.00 Price Valuation
https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_11042025_FBLG_Bautz.pdf
11-05 03:06
FibroBiologics, Inc. - Common Stock Q3 EPS $(0.13) Misses $(0.11) Estimate
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 21.5 percent. This is a 1200 percent decrease over losses of
11-01 04:31
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
Based in Houston, FibroBiologics, a clinical-stage biotech company with over 270 patents, announced that its Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa in Phoenix, Arizona, on October 7, 2025. The presentation will focus on the company's fibroblast-based technologies aimed at addressing unmet medical needs, including the planned initiation of a clinical trial for diabetic foot ulcers in ...
09-23 12:30
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
